Lhasa Limited is a not-for-profit organisation and educational charity that facilitates collaborative data sharing projects in the pharmaceutical, cosmetics and chemistry-related industries.
Lhasa Limited specialises in the development of expert computer systems for toxicity and metabolism prediction. We provide a number of extensive and continually updated knowledge bases and the software needed to interrogate them.
A pioneer in the production of knowledge-based systems for forward thinking scientists, Lhasa Limited continues to draw on over thirty years of experience to create user-friendly, state of the art in silico prediction and database systems for use in metabolism, toxicology and related sciences.
Lhasa Limited was established in 1983 as a not-for-profit company and educational charity. From the outset Lhasa Limited has been owned and controlled by its members, that is, those organisations using our software and working with Lhasa Limited to develop new applications. This continues to be true today.
The founder members of Lhasa Limited were interested in LHASA (Logic and Heuristics Applied to Synthetic Analysis), a computer system originating from and further developed in conjunction with Harvard University, to assist chemists in the design of complex organic molecule syntheses. The aim of the founding members was to fund and support the development and refinement of the transformations (generalised retrosynthetic reactions) in the LHASA knowledge base. Since that time, interest in the LHASA system has diminished and the current membership of Lhasa Limited almost exclusively supports our continued drive for scientific and technological advancement in prediction systems for toxicology and metabolism decision support.
Throughout its history, Lhasa Limited has provided a framework to enable members to contribute knowledge to the development and refinement of structure activity relationships in their field of interest, without compromising the confidentiality of their proprietary data. Lhasa Limited continues to enable organisations to pool their resources, both financial and intellectual, for the benefit of the entire membership and the public at large.
Landmarks in the History of Lhasa Limited
2017 The Vice Lord Lieutenant of West Yorkshire visits Lhasa Limited Head Office to present CEO Chris Barber with a Queen's Award for Enterprise: Innovation, awarded for statistical-based software, Sarah Nexus
2017 Lhasa was named 'Business Master of Innovation' at the Yorkshire Business Masters Awards
2017 Lhasa and Optibrium enter a Research and Product Development Collaboration
2016 Mirabilis is added to the Lhasa product portfolio
2016 Lhasa Limited continues its collaboration with the FDA/CDER (U.S. Food and Drug Administration's Center for Drug Evaluation and Research) by signing a 5 year research collaboration agreement (RCA)
2016 HRH The Duke of Kent visits Lhasa Limited Head Office to present CEO Dave Watson with a Queen’s Award for Enterprise: Innovation, awarded for expert knowledge-based software, Derek Nexus
2016 Recognising the need to adapt both to the requirements of the company and the individual, Lhasa Limited creates a Single Science Team
2016 The first Elemental Impurities Vitic Database is released
2016 Lhasa Limited joins EU-ToxRisk
2015 The Aromatic Amines dataset is released to the Consortium as a Vitic Nexus database for the first time
2015 The iPiE project is initiated
2014 Lhasa Limited releases a complete solution to the ICH M7 Guidelines using its Nexus Platform
2014 Nexus 1.7 is released, which includes the addition of Negative predictions in Derek Nexus and improved reporting
2014 The Genotoxic Impurities (GTI) purge tool project is initiated
2013 Lhasa Limited celebrates its 30th anniversary
2012 The MIP-DILI project is initiated with Lhasa Limited chosen to host the data shared and generated by the project
2012 Lhasa Limited releases Meteor Nexus, providing an integrated solution for metabolism prediction
2012 A new editor for the Derek Nexus system is released
2011 Lhasa Limited continues its collaboration with the FDA/CDER (U.S. Food and Drug Administration's Center for Drug Evaluation and Research) by signing a 5 year research collaboration agreement (RCA).
2011 Lhasa Limited demonstrates its continued commitment to Scientific Strategy through the appointment of a Director of Science
2010 Lhasa Limited joins the eTOX project, hosting and managing all data shared by the major pharmaceutical companies with the new Vitic Nexus Database
2010 The Nexus portfolio continues to expand with the release of Vitic Nexus; a new web-based platform of Lhasa Limited’s chemical management system
2010 Following a 3 year project with external input from members, Lhasa Limited release Zeneth; a tool for the prediction of chemical degradation
2009 Lhasa Limited releases Derek Nexus; the much anticipated successor to Derek for Windows
2008 The first data from the Excipients data sharing initiative is received from the group and entered into the Vitic Excipients database
2008 Lhasa Limited celebrates its 25th anniversary
2007 The Chemical Degradation Project is initiated, with an aim to provide a tool for the prediction of forced chemical degradation reactions
2006 Lhasa Limited signs a 5 year Cooperative Research And Development Agreement (CRADA) with the US Food & Drug Administration
2006 The first data from the Intermediates data sharing initiative is released to the group
2003 The Vitic toxicity database system is launched
2003 Lhasa Limited celebrates its 20th anniversary
2000 Lhasa Limited collaborates with the International Life Sciences Institute (ILSI) to establish the ITIC pilot project for the development of a structure-searchable toxicity database
1999 Lhasa Limited launches the Derek for Windows toxicity prediction system using technology developed through the StAR risk assessment project
1998 Lhasa UK Limited changes its name to Lhasa Limited to reflect the international nature of its business
1993 Lhasa UK Limited joins the StAR risk assessment project
1989 Lhasa UK Limited adopts the DEREK system and coordinates the development of its structure-toxicity knowledge base
1986 The “Electric DEREK ” toxicity prediction system is created at Schering Agrochemicals in the UK
1983 Lhasa UK Limited is created as a not-for-profit and charitable company to coordinate the development of the LHASA knowledge base
1982 The LHASA User’s Group is established in the UK
1980 Peter Johnson brings the LHASA synthesis planning software from Harvard University to the University of Leeds
Board of Directors
Lhasa Limited is a Limited Company and registered charity and, as such, our Directors also act as Trustees of the Charity.
The Lhasa Limited Board of Directors/Trustees is responsible for the governance of the Charity and formally meets on a quarterly basis to review the progress of the Company and to support the work of Company managers under the direction of the Chief Executive Officer.
The current Board of Directors/Trustees consists of the following:
- Dr Susanne Glowienke (Chairman)
- Mr Andy Bowie (Deputy Chairman)
- Dr Camilla Alexander-White (Director/Trustee)
- Dr Richard Brennan (Director/Trustee)
- Ms Samantha Clark (Director/Trustee)
- Dr Krista Dobo (Director/Trustee)
- Professor Val Gillet (Director/Trustee)
- Dr Jim Harvey (Director/Trustee)
- Mr David Hollins (Director/Trustee)
- Dr Edward Lindup (Director/Trustee)
- Dr Debbie Richardson (Immediate Past Chairman)
The Scientific Advisory Board (SAB) provides support and guidance into the scientific direction of Lhasa Limited.
It was formed as a sub-committee of the Board of Directors in June 2006 to provide support for a focus on scientific strategy, allowing the Board of Directors to concentrate on the governance of Lhasa Limited. Like the Board of Directors, the SAB is a voluntary group.
In addition to their contribution to the advancement of existing products, members of the SAB provide invaluable support and input into proposals for the direction of Lhasa Limited’s scientific development.
The SAB is made up of experienced scientists covering a spectrum of disciplines:
- Dr Chris Barber, Chief Executive Officer, Lhasa Limited
- Dr Richard Williams, Chief Scientific Officer, Lhasa Limited
- Dr Andreas Bender, University of Cambridge
- Dr Darren Green, GSK
- Dr Barry Jones, AstraZeneca
- Dr Philip Judson, Judson Consulting
External experts are often invited to some meetings to provide specialist input in a consulting role to assist with specific areas of interest, and other Lhasa Limited staff regularly attend.
Some of the activities covered by the SAB are listed below:
- Suggest topics and partners for collaborative developments
- Comment on issues arising from user group meetings
- Propose and review external research projects initiated as part of charitable activities
- Advise on scientific developments that are relevant to Lhasa Limited and its software and how they might be utilised
- Manage the process for providing detailed external scientific input where considered necessary.
The SAB has already made a significant contribution to the scientific direction of Lhasa Limited and with their further support and the support of our members, our science will continue to meet the needs of all and help us deliver shared knowledge and shared progress.
If you are interested in offering your services as a member of the SAB, please contactor any of the above members.
Visions and Values